Symptom Benefit - Does palliative chemotherapy imoprove symptoms in women with recurrent ovarian cancer? Measuring subjective improvement as well as objective response to estimate the benefit of palliative chemotherapy in women with platinum resistant or refractory ovarian cancer
Symptom Benefit - Does palliative chemotherapy imoprove symptoms in women with recurrent ovarian cancer? Measuring subjective improvement as well as objective response to estimate the benefit of palliative chemotherapy in women with platinum resistant or refractory ovarian cancer
Project number : 245701
Created by: Ylva Storck, 2018-03-21
Last revised by: Ylva Storck, 2018-03-21
Project created in: FoU Region Örebro län

CompletedCompleted
2013-04-01
Rekrytering/datainsamling pågår
2016-06-30
Projektet avslutat

Registeranmälan

  1. Symptom Benefit - Does palliative chemotherapy imoprove symptoms in women with recurrent ovarian cancer? Measuring subjective improvement as well as objective response to estimate the benefit of palliative chemotherapy in women with platinum resistant or refractory ovarian cancer, PUL-anmälan
  2. Symptom Benefit - Does palliative chemotherapy imoprove symptoms in women with recurrent ovarian cancer? Measuring subjective improvement as well as objective response to estimate the benefit of palliative chemotherapy in women with platinum resistant or refractory ovarian cancer, Projektbeskrivning

Titel och sammanfattning

Populärvetenskaplig sammanfattning

Studien vill undersöka olika aspekter av livskvalitet och dess relation till att ha äggstockscancer och behandlas med cytostatika

Projektspecifik information

Ämnesord

checked Cancer och onkologi


(Only selected options are displayed. Click here to display all options)

Studietyp

Prövning av behandling

Randomiserad studie

Nej

Diagnoskod för huvuddiagnos

C51-C58 Maligna tumörer i de kvinnliga könsorganen

Multicenterstudie

Ja

Protokollnummer på prövningen

ANZgog-0701

Etikprövningsmyndighetens diarienummer

2011/1655-31/1

Biobanksavtal

Ej aktuellt

Inklusionsstatus

 Planerat antalAntal tillfrågadeScreen-failureAntal randominserade
n= 1 1 inkluderad

Vetenskaplig sammanfattning

Primary objective: to determine the criteria for defining a clinically significant subjective improvement and the optimal instrument/s for measuring this benefit

Involverade parter

Arbetsplats

Added workplaces

Regioner - Region Örebro Län - Hälso- och sjukvård - Område opererande och onkologi - Onkologiska kliniken workplace verified by Region Örebro län on 2018-06-14

Sponsor

Added workplaces

Annan

Nationell koordinator

Added workplaces

Regioner - Stockholms läns landsting - Karolinska Universitetssjukhuset - Onkologi Thorax - Onkologiska kliniken

Medarbetare i projektet

Louise Bohr Mordhorst
MD, phD, Onkologiska kliniken

Roll i projektet

checked PI (huvudprövare eller ansvarig forskare)

Symptom Benefit - Does palliative chemotherapy imoprove symptoms in women with recurrent ovarian cancer? Measuring subjective improvement as well as objective response to estimate the benefit of palliative chemotherapy in women with platinum resistant or refractory ovarian cancer, from FoU Region Örebro län
http://www.researchweb.org/is/en/fourol/project/245701